Results 211 to 220 of about 193,022 (330)

Delays in diagnosis and treatment of ATTR cardiac amyloidosis: A real‐world data analysis

open access: yesESC Heart Failure, EarlyView.
Abstract Aims and Background Cardiac amyloidosis leads to functional cardiac impairment and heart failure. Transthyretin amyloid cardiomyopathy (ATTR‐CM) is the most common form. After initial suspicion, diagnosis involves imaging techniques, biopsy and genetic tests, prompting transthyretin stabilizer therapy to slow disease progression.
Julia Vogel   +7 more
wiley   +1 more source

Natriuretic peptides modulate monocyte-derived Langerhans cell differentiation and promote a migratory phenotype. [PDF]

open access: yesFront Immunol
Horváth D   +12 more
europepmc   +1 more source

Growth differentiation factor 15, ST2, high‐sensitivity troponin T, and N‐terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction

open access: yesEuropean Journal of Heart Failure, 2012
Rajalakshmi Santhanakrishnan   +13 more
semanticscholar   +1 more source

Real‐world use of guideline‐directed therapy for heart failure: Insights from the Danish Heart Failure Registry

open access: yesESC Heart Failure, EarlyView.
Our study examined the real‐world implementation of guideline‐directed medical therapy (GDMT) and its association with mortality and hospitalization in 46 816 patients with heart failure with reduced ejection fraction (HFrEF) from the Danish Heart Failure Registry (2008–2022).
Inge Schjødt   +5 more
wiley   +1 more source

Pre‐admission beta‐blocker therapy and outcomes in cardiogenic shock: Insights from the Altshock‐2 Registry

open access: yesESC Heart Failure, EarlyView.
Among 668 with cardiogenic shock included in the multicentre prospective Altshock‐2 registry, 299 patients (44.8%) received pre‐admission beta‐blocker therapy. Previous beta‐blocker therapy influenced the early hemodynamic response to vasoactive drugs, but it was not associated with in‐hospital mortality.
Matteo Pagnesi   +21 more
wiley   +1 more source

Home - About - Disclaimer - Privacy